The Royal Pharmaceutical Society of Great Britain (RPS) has made new recommendations to increase the use of pharmacist independent prescribers (PIP) in the UK.
Sensorion has received acceptance from the European Medicines Agency (EMA) on its Paediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in two indications.